Type i interferon blocking agents for prevention and treatment of psoriasis

A technology of interferon and blocking agent, applied in the field of type I interferon blocking agent, can solve the problems of not long-term treatment, limited effect of psoriasis, high potential toxicity and the like

Inactive Publication Date: 2007-10-17
UNIV ZURICH
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no indication that IFN-α2 antagonists should be used
[0009] There is a need for new psoriasis treatments as current treatments for psoriasis are limited by their limited efficacy, side effects and failure to prevent new relapses
Although newer agents such as anti-TNF-α targeted therapy can induce rapid disease remission, they are not an option for long-term treatment due to their high potential toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Type i interferon blocking agents for prevention and treatment of psoriasis
  • Type i interferon blocking agents for prevention and treatment of psoriasis
  • Type i interferon blocking agents for prevention and treatment of psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0041] Quantitative real-time PCR. Total RNA was extracted from homogenized skin samples and reverse transcribed as previously described [Boyman et al., J Exp Med 2004, 199:731-736]. Quantitative analysis by real-time PCR with primers designed against most of the human IFN-α sequences (purchased from Applied Biosystems, Foster City, Canada) and against human IRF-7 (left, TCCCCACGCTATACCATCTACCT-3'; right, ACAGCCAGGGTTCCAGCTT-3') Complementary DNA was used to analyze the expression of IFN-α and IRF-7 transcripts. Normalization was performed with 18S ribosomal RNA. In the humanized mouse model, IFN-α quantification was performed with a primer kit (purchased from Search-LC, Heidelberg, Germany) that recognizes most of the human IFN-α genes but not their mouse counterparts. Human GAPDH mRNA levels were quantified with human-specific primers (left, ATTGCCCTCAACGACCACTTTG-3'; right, TTGATGGTACATGAAAGGTGAGG-3') and used for normalization.

[0042] Animal and Transplantation Procedu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist (e.g. an anti-IFN-a antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.

Description

technical field [0001] The invention relates to the use of type I interferon blocking agent for preparing medicine for preventing and treating psoriasis, and the method for preventing and treating psoriasis by using type I interferon blocking agent. Background technique [0002] Psoriasis is a common autoimmune-related inflammatory disease affecting human skin. There is very convincing evidence that, like Crohn's disease and rheumatoid arthritis, psoriasis is due to an apparently self-sustaining activation of autoreactive IFN-γ-secreting T cells. The initial onset of skin lesions is followed by chronic recurrence of the disease, typically triggered by environmental factors including infection, mechanical stress, and medications. These lesions have been proposed to lead to pathogenic T-cell cascades through as yet unidentified innate immune responses. [0003] Plasmacytoid dendritic cell precursors (PDCs) are key effectors in natural antiviral immunity due to their unique a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395
CPCC07K16/28A61K2039/505C07K2316/96C07K2317/73C07K2317/76A61P17/06A61P37/06A61P43/00A61K39/395A61K38/21
Inventor 米歇尔·吉列弗兰克·O·内斯特尔
Owner UNIV ZURICH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap